KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Moderna (MRNA) Receivables - Net (2017 - 2025)

Moderna (MRNA) has disclosed Receivables - Net for 9 consecutive years, with $368.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 2.79% to $368.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $368.0 million, a 2.79% increase, with the full-year FY2025 number at $368.0 million, up 2.79% from a year prior.
  • Receivables - Net was $368.0 million for Q4 2025 at Moderna, down from $1.0 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $3.2 billion in Q1 2021 to a low of $36.0 million in Q2 2025.
  • A 5-year average of $1.5 billion and a median of $1.2 billion in 2022 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: soared 57047.94% in 2021, then plummeted 91.38% in 2023.
  • Moderna's Receivables - Net stood at $3.2 billion in 2021, then tumbled by 56.38% to $1.4 billion in 2022, then plummeted by 35.6% to $892.0 million in 2023, then crashed by 59.87% to $358.0 million in 2024, then grew by 2.79% to $368.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Receivables - Net are $368.0 million (Q4 2025), $1.0 billion (Q3 2025), and $36.0 million (Q2 2025).